1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Serbia Pharmaceuticals and Healthcare Report Q4 2016

Serbia Pharmaceuticals and Healthcare Report Q4 2016

  • September 2016
  • -
  • Business Monitor International
  • -
  • 81 pages

Includes 3 FREE quarterly updates

BMI View:

Serbia will remain an unattractive market for multinational drugmakers in comparison to itsregional neighbours. Government cost-containment, via severe drug price cuts, and continued economicissues will dampen the country's growth outlook.

Headline Expenditure Projections

Pharmaceuticals: RSD91.42bn (USD840mn) in 2015 to RSD88.08bn (USD766mn) in 2016; -3.7% inlocal currency terms and -8.8% in US dollar terms. Forecast unchanged from Q316.Healthcare: RSD405.24bn (USD3.73bn) in 2015 to RSD414.284bn (USD3.60bn) in 2016; 2.2% in localcurrency terms and -3.3% in US dollar terms. Forecast unchanged from Q316.Risk/Reward IndexIn our Q416 Pharmaceutical Risk/Reward Index (RRI), Serbia is ranked 18th out of 20 markets in theCentral and Eastern European (CEE) matrix with an unchanged score of 43.0 compared with the previousquarter. Its position also remains unchanged, sitting one place above Uzbekistan (36.5) and just belowKazakhstan (45.9). Serbia scores considerably below the regional average score of 52.4 in Q416. Serbia willcontinue to be a challenging market for foreign investors, because of the prevalence of corruption, a largescaleblack-market economy, and the poor state of the country's infrastructure and finances, in both publicand private spheres.

Table Of Contents

Serbia Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Serbia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Serbia 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Serbia 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Serbia 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Serbia 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Serbia 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Serbia 2012-2020) 22
Generic Drug Market Forecast 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Serbia 2012-2020) 24
OTC Medicine Market Forecast 25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Serbia 2012-2020) 26
Pharmaceutical Trade Forecast 27
Table: Pharmaceutical Trade Data And Forecasts (Serbia 2014-2020) 28
Table: Pharmaceutical Trade Data And Forecasts local currency (Serbia 2014-2020) 29
Industry Risk/Reward Index 30
Central And Eastern Europe Risk/Reward Index - Q4 2016 30
Serbia Risk/Reward Index 37
Rewards 37
Risks 38
Regulatory Review 40
Intellectual Property Environment 41
Pricing Regime 45
Reimbursement Regime 47
Market Overview 49
Healthcare Sector 50
Table: Healthcare Resources (Serbia 2010-2015) 53
Table: Healthcare Personnel (Serbia 2010-2015) 53
Table: Healthcare Activity (Serbia 2010-2015) 54
Research and Development 54
Clinical Trials 55
Epidemiology 56
Competitive Landscape 60
Research-Based Industry 60
Table: Multinational Market Activity 60
Generic Drugmakers 61
Pharmaceutical Distribution 61
Pharmaceutical Retail Sector 62
Company Profile 63
Galenika 63
Hemofarm (Stada) 67
Demographic Forecast 71
Table: Population Headline Indicators (Serbia 2005-2025) 72
Table: Population By Age Group (Serbia 2005-2025) 72
Table: Population By Age Group % (Serbia 2005-2025) 73
Glossary 75
Methodology 77
Pharmaceutical Expenditure Forecast Model 77
Healthcare Expenditure Forecast Model 77
Notes On Methodology 78
Risk/Reward Index Methodology 79
Index Overview 80
Table: Pharmaceutical Risk/Reward Index Indicators 80
Indicator Weightings 81

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.